We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
+$34.2M
Cap. Flow %
1.92%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.24%
2 Healthcare 10.61%
3 Energy 0.15%
4 Communication Services 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
26
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$15.9M 0.89%
+3,497
New +$167K
ITMN
27
PUT
DELISTED
INTERMUNE INC
ITMN
$15.7M 0.88%
4,681
+2,843
+155% +$63.3K
PCYC
28
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$15.3M 0.86%
1,529
+1,456
+1,995% +$189K
ABBV icon
29
PUT
AbbVie
ABBV
$464B
$15.3M 0.86%
+2,979
New +$151K
PCYC
30
CALL
DELISTED
PHARMACYCLICS INC
PCYC
$15M 0.84%
+1,500
New +$195K
AMGN icon
31
PUT
Amgen
AMGN
$204B
$14M 0.79%
+1,138
New +$138K
PFE icon
32
CALL
Pfizer
PFE
$157B
$13.8M 0.77%
+4,533
New +$135K
CLVS
33
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$13.4M 0.75%
1,931
+1,897
+5,579% +$139K
TMO icon
34
CALL
Thermo Fisher Scientific
TMO
$236B
$13.2M 0.74%
+1,100
New +$131K
TENX icon
35
Tenax Therapeutics
TENX
$68.5M
$11.8M 0.66%
+66
New +$13.1M
MRK icon
36
CALL
Merck
MRK
$355B
$11.4M 0.64%
2,113
-11,335
-84% -$587K
ACAD icon
37
Acadia Pharmaceuticals
ACAD
$4.63B
$11.3M 0.63%
463,146
-93,867
-17% -$2.37M
GEVA
38
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$11M 0.62%
+1,331
New +$123K
GILD icon
39
Gilead Sciences
GILD
$181B
$11M 0.62%
155,073
+77,073
+99% +$6.04M
AUXL
40
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$10.8M 0.61%
+3,983
New +$106K
AGN
41
PUT
DELISTED
Allergan Inc
AGN
$10.7M 0.6%
863
-753
-47% -$91.7K
IWM icon
42
PUT
iShares Russell 2000 ETF
IWM
$76.9B
$10.4M 0.58%
+890
New +$103K
LLY icon
43
CALL
Eli Lilly
LLY
$1.01T
$10.1M 0.57%
+1,719
New +$95.9K
SRPT icon
44
PUT
Sarepta Therapeutics
SRPT
$2.21B
$9.76M 0.55%
4,060
-3,413
-46% -$87K
IONS icon
45
PUT
Ionis Pharmaceuticals
IONS
$7.87B
$8.98M 0.5%
2,078
-258
-11% -$12.5K
KERX
46
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$8.93M 0.5%
5,238
+4,646
+785% +$70.1K
BPTH
47
DELISTED
Bio-Path Holdings Inc
BPTH
$8.78M 0.49%
+828
New +$10.3M
MNKD icon
48
PUT
MannKind Corp
MNKD
$1.15B
$8.49M 0.48%
4,222
+886
+27% +$25.2K
SRPT icon
49
Sarepta Therapeutics
SRPT
$2.21B
$8.46M 0.47%
352,100
-155,600
-31% -$3.97M
OPK icon
50
Opko Health
OPK
$1.17B
$7.75M 0.43%
+831,237
New +$7.29M
1
2
3 4 5

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management's Q1 2014 filing shows 107 new, 59 increased, 54 reduced and 92 closed positions. Its largest new stake was Tenax Therapeutics: 66 shares worth $11.8M. The largest sale was MannKind Corp, an estimated $22.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Energy.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.